Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma.

Huwyler, Fabrizio; Kunz, Rebekka; Bacher, Ulrike; Hoffmann, Michèle; Novak, Urban; Daskalakis, Michael; Banz, Yara; Pabst, Thomas (2023). Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma. Cancers, 15(7) MDPI AG 10.3390/cancers15072091

[img]
Preview
Text
cancers-15-02091.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (566kB) | Preview

(1) Background: First-line therapy in fit MCL patients may comprise high-dose chemotherapy (HDCT) with autologous transplantation to consolidate remission before maintenance treatment. However, optimization of HDCT is an unmet clinical need given the substantial relapse rate of first-line treatment, while the use of bortezomib is a promising candidate to be added to standard HDCT. (2) Methods: We analyzed 11 consecutive patients with MCL who received bortezomib added to standard BeEAM (2BeEAM) HDCT at a single academic institution. We assessed safety, feasibility, toxicities, and survival rates. (3) Results: All patients had stage III or IV disease. We found that six patients (55%) developed new or worsening of preexisting peripheral neuropathy following administration of 2BeEAM HDCT. One patient relapsed within the first six months after HDCT, whereas three patients never reached complete remission. After a median follow-up of 22 months, the PFS was 64% and the OS 64% at the last follow-up assessment. At this time, 55% of patients were in CR. (4) Conclusions: The use of bortezomib added to standard BeEAM HDCT is associated with relevant toxicities, particularly with regards to additional neuropathy. Moreover, the anti-lymphoma efficacy of 2BeEAM HDCT appears to be modest; therefore, other therapeutic options should be evaluated for consolidation in this patient group.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology
04 Faculty of Medicine > Service Sector > Institute of Pathology > Clinical Pathology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory
04 Faculty of Medicine > Pre-clinic Human Medicine > Institute of Anatomy

UniBE Contributor:

Huwyler, Fabrizio Alexander Francis, Bacher, Vera Ulrike, Hoffmann, Michèle, Novak, Urban, Daskalakis, Michael, Banz Wälti, Yara Sarah, Pabst, Thomas Niklaus

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2072-6694

Publisher:

MDPI AG

Language:

English

Submitter:

Pubmed Import

Date Deposited:

14 Apr 2023 14:03

Last Modified:

14 Apr 2023 15:41

Publisher DOI:

10.3390/cancers15072091

PubMed ID:

37046753

Uncontrolled Keywords:

BeEAM bortezomib feasibility and toxicity high-dose chemotherapy mantle cell lymphoma

BORIS DOI:

10.48350/181708

URI:

https://boris.unibe.ch/id/eprint/181708

Actions (login required)

Edit item Edit item
Provide Feedback